Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX43 in previously treated advanced or metastatic hepatocellular carcinoma
CTR20244832Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HLX43 in hepatocellular carcinoma (HCC) (3 arms), sponsored by HyBioPharma. Primary endpoints: Objective response rate and Progression-free survival. Started Mar 2025; status: active.
02
Drugs
HLX43
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20244832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244832.